Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 195

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A Multicentre, Randomized, Double-Blinded, Placebo-Controlled Phase III Study to Investigate Extending the Time for Thrombolysis in Emergency Neurological Deficits (EXTEND)

Open access
Ma, Henry, Parsons, Mark W., Christensen, Soren, Campbell, Bruce C. V., Churilov, Leonid, Connelly, Alan, Yan, Bernard, Bladin, Chris, Phan, Than, Barber, Alan P., Read, Stephen, Hankey, Graeme J., Markus, Romesh, Wijeratne, Tissa, Grimley, R., Mahant, N., Kleinig, Tim, Sturm, John, Lee, A., Blacker, D., Gerraty, Richard, Krause, M., Desmond, P. M., McBride, S. J., Carey, Leanne, Howells, David W., Hsu, C. Y., Davis, Stephen M., Donnan, Geoffrey A., on behalf of the EXTEND investigators · 2012 · International Journal of Stroke

Abstract

Background and hypothesis: Thrombolytic therapy with tissue plasminogen activator is effective for acute ischaemic stroke within 4·5 h of onset. Patients who wake up with stroke are generally ineligible for stroke thrombolysis. We hypothesized that ischaemic stroke patients with significant penumbral mismatch on either magnetic resonance imaging or computer tomography at three- (or 4·5 depending on local guidelines) to nine-hours from stroke onset, or patients with wake-up stroke within nine-hours from midpoint of sleep duration, would have improved clinical outcomes when given tissue plasminogen activator compared to placebo. Study design: EXtending the time for Thrombolysis in Emergency Neurological Deficits is an investigator-driven, Phase III, randomized, multicentre, double-blind, placebo-controlled study. Ischaemic stroke patients presenting after the three- or 4·5-h treatment window for tissue plasminogen activator and within nine-hours of stroke onset or with wake-up stroke within nine-hours from the midpoint of sleep duration, who fulfil clinical (National Institutes of Health Stroke Score ≥4–26 and prestroke modified Rankin Scale <2) will undergo magnetic resonance imaging or computer tomography. Patients who also meet imaging criteria (infarct core volume <70 ml, perfusion lesion : infarct core mismatch ratio >1·2, and absolute mismatch >10 ml) will be randomized to either tissue plasminogen activator or placebo. Study outcome: The primary outcome measure will be modified Rankin Scale 0–1 at day 90. Clinical secondary outcomes include categorical shift in modified Rankin Scale at 90 days, reduction in the National Institutes of Health Stroke Score by 8 or more points or reaching 0–1 at day 90, recurrent stroke, or death. Imaging secondary outcomes will include symptomatic intracranial haemorrhage, reperfusion and or recanalization at 24 h and infarct growth at day 90.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1747-4949.2011.00730.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 195

Metadata

Authors
Ma, H., Parsons, M. W., Christensen, S., Campbell, B. C. V., Churilov, L., Connelly, A., Yan, B., Bladin, C., Phan, T., Barber, A. P., Read, S., Hankey, G. J., Markus, R., Wijeratne, T., Grimley, R., Mahant, N., Kleinig, T., Sturm, J., Lee, A., Blacker, D., Gerraty, R., Krause, M., Desmond, P. M., McBride, S. J., Carey, L., Howells, D. W., Hsu, C. Y., Davis, S. M., Donnan, G. A., & on behalf of the EXTEND investigators
Venue
International Journal of Stroke
Published
2011-12-20
Volume
7
Issue
1
Pages
74-80
ISSN
  • 1747-4930 (ISSN-L)
  • 1747-4949
OpenAlex
W2033967446
Cited by
195
References
1
FWCI
16.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Multicentre, Randomized, Double-Blinded, Placebo-Controlled Phase III Study to Investigate Extending the Time for Thrombolysis in Emergency Neurological Deficits (EXTEND). https://app.cochat.ai/papers/10.1111/j.1747-4949.2011.00730.x
The paper
Ma, H., Parsons, M. W., Christensen, S., Campbell, B. C. V., Churilov, L., Connelly, A., Yan, B., Bladin, C., Phan, T., Barber, A. P., Read, S., Hankey, G. J., Markus, R., Wijeratne, T., Grimley, R., Mahant, N., Kleinig, T., Sturm, J., Lee, A., . . . on behalf of the EXTEND investigators. (2012). A Multicentre, Randomized, Double-Blinded, Placebo-Controlled Phase III Study to Investigate Extending the Time for Thrombolysis in Emergency Neurological Deficits (EXTEND). International Journal of Stroke. https://doi.org/10.1111/j.1747-4949.2011.00730.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.